Table 1 |
||||||
|
Recent literature on the role of corticosteroids in severe community-acquired pneumonia |
||||||
| Reference |
Study design |
Sample size, number |
Patient selection |
Corticosteroids (drug/regimen) |
Primary endpoints |
Level of evidence and recommendation |
|
|
||||||
| Marik, et al. [21] |
Single-center RCT |
30 |
Severe CAP |
Hydrocortisone 10 mg/kg versus placebo 30 minutes before antibiotics |
Mortality, clinical course, and serum TNF-α levels |
Weak recommendation, moderate-quality evidence |
| Confalonieri, et al. [6] |
Multicenter RCT |
46 |
Severe CAP |
Hydrocortisone 200 mg + hydrocortisone 10 mg/hour, for 7 days versus placebo |
Mortality, clinical course, and Systemic inflammation |
Strong recommendation, moderate-quality evidence |
| Mikami, et al. [20] |
Open label RCT |
31 |
Moderate and severe CAP |
Prednisolone 40 mg qd, for 3 days versus placebo |
Mortality and clinical course |
Weak recommendation, low-quality evidence |
| Garcia-Vidal, et al. [19] |
Retrospective cohort study |
308 |
Severe CAP |
Methylprednisolone 45 mg (or equivalent) qd for 11.4 days |
Mortality |
Strong recommendation, low-quality evidence |
|
|
||||||
|
CAP, community-acquired pneumonia; qd, quaque die (every day); RCT, randomized controlled trial; TNF-α, tumor necrosis factor-alpha. |
||||||
|
Salluh et al. Critical Care 2008 12:434 doi:10.1186/cc7107 |
||||||